Keywords
hypercholesterolemia
HydroxymethylglutarylCoA Reductase Inhibitors
evolocumab
HydroxymethylglutarylCoA Reductase Inhibitors
evolocumab
How to Cite
Parra, G. A., Lindarte, H. H., & Rubio, A. F. (2020). Over optimum response to PCSK-9 inhibitors: ¿is it mandatory to supply them every 2 weeks?, about a case. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 7(1), 43–44. https://doi.org/10.53853/encr.7.1.568
Abstract
The PCSK-9 inhibitors are presented as an excellent alternative treatment in those cases of hypercholesterolemia that do not reach goals with high intensity statin treatment and ezetimibe, additionally in patients with statin intolerance who need to have LDL cholesterol goals. In this case we expose the possibility to treat to target LDL goals and use PCSK-9i later than 2 weeks.
References
1. Alenghat FJ, Davis AM. Management of blood cholesterol. JAMA. 2019;321(8):800-1.
2. Cicero AF, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2018;14(1):9-15.
3. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes. Diabetes Care. 2019;2(1):S103-23.
2. Cicero AF, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2018;14(1):9-15.
3. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes. Diabetes Care. 2019;2(1):S103-23.
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent. A copy may be reviewed here